Sutro Biopharma Inc [NASDAQ: STRO] gained 44.44% on the last trading session, reaching $1.30 price per share at the time.
If compared to the average trading volume of 1.59M shares, STRO reached a trading volume of 4574645 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Sutro Biopharma Inc [STRO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for STRO shares is $5.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on STRO stock is a recommendation set at 2.36. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Sutro Biopharma Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 17, 2025. While these analysts kept the previous recommendation, Wedbush dropped their target price from $8 to $2. The new note on the price target was released on March 14, 2025, representing the official price target for Sutro Biopharma Inc stock. On March 14, 2025, analysts decreased their price target for STRO shares from 11 to 1.
The Average True Range (ATR) for Sutro Biopharma Inc is set at 0.14, with the Price to Sales ratio for STRO stock in the period of the last 12 months amounting to 1.77. The Price to Book ratio for the last quarter was 2.41, with the Price to Cash per share for the same quarter was set at 3.76.
Trading performance analysis for STRO stock
Sutro Biopharma Inc [STRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 140.74. With this latest performance, STRO shares gained by 73.33% in over the last four-week period, additionally sinking by -64.29% over the last 6 months – not to mention a drop of -65.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for STRO stock in for the last two-week period is set at 70.68, with the RSI for the last a single of trading hit 82.12, and the three-weeks RSI is set at 61.54 for Sutro Biopharma Inc [STRO]. The present Moving Average for the last 50 days of trading for this stock 1.0732, while it was recorded at 0.7994 for the last single week of trading, and 2.6855 for the last 200 days.
Sutro Biopharma Inc [STRO]: A deeper dive into fundamental analysis
Sutro Biopharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.60.
Sutro Biopharma Inc [STRO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for STRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sutro Biopharma Inc go to 32.32%.
An analysis of Institutional ownership at Sutro Biopharma Inc [STRO]
There are presently around $79.73%, or 83.15%% of STRO stock, in the hands of institutional investors. The top three institutional holders of STRO stocks are: SUVRETTA CAPITAL MANAGEMENT, LLC with ownership of 7.71 million shares, which is approximately 9.4906%. BLACKROCK INC., holding 6.91 million shares of the stock with an approximate value of $$20.25 million in STRO stocks shares; and BLACKROCK INC., currently with $$13.03 million in STRO stock with ownership which is approximately 5.4757%.
